PTEN and glioblastoma: This combined sonodynamic and immune therapy approach significantly extended the median survival time in orthotopic GL261 and PTEN-deficient immunosuppressive CT2A GBM mouse models, demonstrating its potential for synergistic and effective cancer treatment [193].